Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003575 · ClinicalTrials.gov registry record · Phase 2
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00003575: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00003575 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003575, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Phase II trial to compare the effectiveness of interleukin-12 following chemotherapy in treating patients who have refractory HIV-associated non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person' white blood cells to kill cancer cells.
Interventions
- DRUG etoposide
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- BIOLOGICAL recombinant interleukin-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1999-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003575
The ClinicalTrials.gov registry entry for NCT00003575 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which etoposide is the first listed.
NCT00003575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003575 about?
NCT00003575 is a clinical study titled "Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma". Phase II trial to compare the effectiveness of interleukin-12 following chemotherapy in treating patients who have refractory HIV-associated non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-12 may kill tu...
What is the current status of trial NCT00003575?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1999-01.
What interventions are being tested in trial NCT00003575?
The interventions under investigation include: etoposide (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003575?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.